viral
infect
close
link
wheez
ill
children
age
respiratori
syncyti
viru
rsv
main
caus
agent
bronchiol
wherea
rhinoviru
rv
commonli
detect
wheez
children
thereaft
sever
respiratori
ill
induc
either
virus
associ
subsequ
develop
asthma
risk
greatest
young
children
wheez
rv
infect
whether
viral
ill
actual
caus
asthma
subject
intens
debat
rsvinduc
wheez
ill
infanc
influenc
respiratori
health
year
definit
evid
rsvinduc
bronchiol
damag
airway
promot
airway
obstruct
recurr
wheez
rv
like
caus
less
structur
damag
yet
signific
contributor
wheez
ill
young
children
context
asthma
virus
interact
viral
virul
factor
person
risk
factor
eg
genet
environment
exposur
eg
airway
microbiom
promot
sever
wheez
ill
risk
progress
asthma
addit
allergi
asthma
major
risk
factor
frequent
sever
rvrelat
ill
treatment
inhibit
inflamm
efficaci
rvinduc
wheez
wherea
antirsv
mab
palivizumab
decreas
risk
sever
rsvinduc
ill
subsequ
recurr
wheez
develop
greater
understand
person
environment
factor
promot
sever
viral
ill
might
lead
new
strategi
prevent
viral
wheez
ill
perhap
reduc
subsequ
risk
asthma
j
allergi
clin
immunol
abbrevi
use
cadherinrel
famili
member
nbreg
neonat
regulatori
b
ngf
nerv
growth
factor
odd
ratio
rsv
respiratori
syncyti
viru
rv
rhinoviru
tlr
tolllik
receptor
discuss
articl
jaci
journal
club
blog
wwwjacionlineblogspotcom
bronchiol
acut
wheez
ill
asthma
huge
clinic
burden
preval
bronchiol
approxim
first
year
second
year
life
children
acut
wheez
least
school
age
recurr
wheez
eventu
preval
asthma
approxim
children
diagnost
viral
respiratori
tract
infect
improv
markedli
last
decad
develop
pcr
techniqu
sever
new
respiratori
virus
subgroup
discov
especi
rhinoviru
rv
diagnost
markedli
improv
learn
bronchiol
earli
wheez
episod
almost
alway
case
associ
viral
infect
overal
viru
detect
rate
slightli
decreas
age
older
children
predict
childhood
asthma
limit
mani
year
assess
tradit
risk
factor
atop
characterist
aeroallergen
sensit
increas
blood
eosinophil
count
atop
eczema
parent
asthma
factor
relat
parent
atopi
acut
wheez
ill
rv
respiratori
syncyti
viru
rsv
earli
marker
recurr
wheez
addit
rvinduc
wheez
episod
infanc
major
risk
factor
later
asthma
especi
children
atop
featur
asthma
establish
exposur
allergen
rv
infect
import
trigger
asthma
exacerb
children
review
focu
role
viral
infect
develop
exacerb
asthma
children
understand
mechan
event
could
suggest
novel
insight
pathogenesi
asthma
would
help
identifi
novel
strategi
prevent
treatment
asthma
bronchiol
virusinduc
infect
inflamm
small
bronchiol
surround
tissu
clinic
character
first
expiratori
breath
difficulti
children
less
year
age
lower
respiratori
tract
symptom
includ
dri
cough
tachypnea
hyperinfl
chest
retract
widespread
crackl
wheez
mani
studi
wheez
mandatori
diagnost
criterion
upper
age
limit
vari
month
year
wheez
defin
whistl
sound
expir
accompani
dyspnea
wheez
diagnos
revers
expiratori
airway
obstruct
ill
fulfil
diagnosi
bronchiol
asthma
moreov
wheez
divid
differ
phenotyp
base
natur
histori
transient
earli
persist
lateonset
wheez
typic
latter
phenotyp
close
associ
sensit
asthma
asthma
chronic
disord
character
airway
inflamm
increas
mucu
secret
bronchial
hyperrespons
caus
revers
airflow
obstruct
chronic
inflamm
disrupt
epithelium
airway
remodel
increas
suscept
mani
environment
factor
viral
infect
allergen
rv
nonenvelop
positivestrand
rna
virus
famili
picornavirida
genu
enteroviru
classifi
speci
rva
rvb
rvc
fig
distinct
rv
genotyp
includ
rva
rvb
serotyp
newli
identifi
rvc
serotyp
rv
structur
genet
variabl
inhibit
effort
develop
antivir
exampl
small
molecul
capsid
bind
agent
inhibit
rva
rvb
bind
replic
effect
rvc
differ
capsid
structur
proteas
inhibitor
effect
vitro
result
clinic
trial
disappoint
larg
number
antigen
distinct
rv
type
barrier
vaccin
develop
although
new
approach
identifi
degre
crossreact
among
rv
type
highli
multiplex
rv
vaccin
immunogen
anim
model
detect
epidemiolog
rvc
grow
convent
cell
cultur
delay
discoveri
approxim
year
first
discoveri
rv
pcr
method
choic
identifi
rv
nasal
mucu
sampl
asymptomat
subject
posit
result
rv
viru
caus
chronic
infect
colon
healthi
subject
symptomat
asymptomat
infect
induc
system
immun
respons
young
wheez
children
rv
circul
yearround
multipl
coexist
genotyp
peak
preval
temper
climat
occur
earli
autumn
late
spring
infect
caus
common
cold
symptom
preval
rvinduc
bronchiolitiswheez
age
depend
children
hospit
lower
respiratori
tract
ill
rsv
detect
often
month
age
rv
common
older
children
rv
predomin
etiolog
agent
wheez
episod
asthma
exacerb
children
infant
age
less
month
rv
caus
approxim
bronchiol
acut
wheez
episod
emerg
depart
hospit
set
second
rsv
rv
also
lead
caus
bronchiol
lead
hospit
outsid
winter
rsvinduc
bronchiol
season
rva
rvc
speci
caus
sever
respiratori
ill
rvb
speci
schoolag
asthma
rvinduc
bronchiol
wheez
rvinduc
sever
bronchiolitisearli
wheez
robust
marker
asthma
risk
wheez
episod
caus
rsv
virus
tabl
highrisk
birth
cohort
includ
wheez
children
least
atop
parent
shown
close
associ
earlylif
rvinduc
wheez
schoolag
asthma
childhood
origin
asthma
coast
studi
demonstr
risk
asthma
age
year
increas
children
wheez
rv
odd
ratio
versu
rsv
first
year
furthermor
children
rvinduc
wheez
third
year
life
asthma
age
year
although
rvinduc
wheez
independ
asthma
risk
factor
aeroallergen
sensit
markedli
increas
rvassoci
risk
asthma
australian
birth
cohort
studi
show
risk
wheez
age
year
increas
wheez
less
year
age
associ
rv
either
alon
concomit
rsv
children
sensit
age
less
year
therefor
data
highrisk
birth
cohort
suggest
atop
airway
increas
suscept
longterm
dysfunct
rvinduc
wheez
ill
addit
subsequ
asthma
risk
also
demonstr
populationbas
longterm
followup
studi
children
hospit
wheez
episod
finnish
studi
asthma
age
year
common
rvinduc
rsvinduc
sever
bronchiol
prospect
studi
viral
wheez
episod
infanc
associ
increas
asthma
risk
long
year
one
studi
focus
first
episod
sever
wheez
demonstr
associ
rv
schoolag
atop
asthma
followup
upper
age
limit
bronchiol
set
month
nonrsvinduc
bronchiol
case
rv
induc
shown
higher
asthma
risk
age
year
rsvinduc
bronchiol
associ
rvinduc
wheez
develop
childhood
asthma
confirm
recent
metaanalysi
includ
origin
articl
rsv
rsv
pneumoviru
paramyxovirida
famili
singlestrand
envelop
rna
viru
major
antigen
group
b
fig
genet
divers
protein
among
b
rsv
group
form
sever
subgroup
genotyp
b
genotyp
evid
strain
like
caus
lower
airway
diseas
virul
factor
identifi
monoclon
antibodi
rsv
fusion
f
protein
inhibit
viral
attach
sever
clinic
ill
rsv
vaccin
elus
sever
candid
clinic
develop
detect
epidemiolog
rapid
rsv
antigen
detect
pcr
appear
equal
sensit
detect
viru
howev
former
use
often
clinic
decis
make
rsv
caus
bronchiol
case
peak
incid
infant
month
age
epidem
occur
typic
midwint
nearli
children
rsv
infect
age
year
first
year
life
approxim
requir
outpati
medic
care
wherea
sever
ill
need
hospit
caus
rsvinduc
bronchiolitispneumonia
risk
factor
sever
rsvinduc
bronchiol
age
less
month
prematur
presenc
chronic
lung
diseas
congenit
heart
diseas
immunodefici
neuromuscular
disord
childhood
asthma
rsvinduc
bronchiol
mani
prospect
longterm
followup
studi
shown
rsvinduc
bronchiol
associ
later
develop
asthma
exampl
tucson
respiratori
studi
link
rsvinduc
bronchiol
asthma
age
year
finnish
studi
link
rsvinduc
bronchiol
selfreport
asthma
age
year
casecontrol
studi
swedish
children
report
associ
rsvinduc
bronchiol
subsequ
allerg
sensit
find
reproduc
birth
cohort
studi
whether
associ
causal
subject
consider
debat
retrospect
cohort
studi
includ
infant
show
infant
born
month
rsv
season
greatest
risk
hospit
lower
respiratori
tract
ill
highest
risk
asthma
age
year
suggest
causal
danish
studi
includ
danish
twin
reach
differ
conclus
sever
rsvinduc
ill
associ
recurr
wheez
earli
childhood
attribut
genet
predisposit
sever
rsvinduc
ill
asthma
two
studi
rsv
immunoprophylaxi
palivizumab
preterm
highrisk
infant
demonstr
prevent
sever
rsvinduc
ill
decreas
recurr
wheez
atop
asthma
sever
differ
rvand
rsvinduc
ill
respect
atrisk
popul
clinic
characterist
children
hospit
rvinduc
wheez
tend
older
like
wheez
previous
often
allerg
sensit
compar
rsvinduc
wheez
also
show
favor
respons
oral
corticosteroid
treatment
wherea
rsvinduc
wheez
although
rsv
gener
caus
sever
infect
infant
rv
incept
wheez
might
rapid
durat
shorter
rv
compar
rsv
infect
observ
support
cluster
analysi
includ
children
bronchiol
identifi
show
differ
distinct
clinic
profil
pathophysiolog
rv
rsv
transmit
mainli
direct
contact
aerosol
particl
virus
replic
ciliat
epitheli
cell
upper
airway
mediumto
larges
lower
airway
fig
rsv
infect
extend
small
airway
also
infect
type
pneumocyt
virus
attach
uniqu
cellular
receptor
intercellular
adhes
molecul
use
rvb
rva
lowdens
lipoprotein
receptor
use
rva
cadherinrel
famili
member
use
rvc
use
rsv
rsv
induc
epitheli
cell
apoptosi
necrosi
gener
caus
damag
airway
epithelium
compar
rv
surfact
protein
shown
protect
effect
rsv
infect
regul
innat
adapt
immun
particip
host
defens
pathway
regul
proinflammatori
cytokin
product
chemotaxi
tissu
repair
rv
attach
infect
cell
recogn
rv
pathogenassoci
molecular
pattern
interact
differ
famili
pattern
recognit
receptor
tolllik
receptor
tlr
retino
acidinduc
gene
ilik
receptor
key
regul
innat
adapt
immun
respons
rsv
infect
receptor
activ
transcript
factor
eg
interferon
regulatori
transcript
factor
nuclear
factor
kb
promot
express
type
type
iii
interferon
sever
inflammatori
cytokin
gene
earli
innat
immun
respons
type
interferon
occur
rapidli
either
rv
rsv
infect
epithelium
virus
induc
cytokin
tnf
ifng
chemokin
growth
factor
activ
attract
granulocyt
dendrit
cell
monocyt
site
infect
transcript
profil
pbmc
rsv
infect
demonstr
stimul
innat
immun
cellcycl
pathway
downregul
b
cellrel
gene
latter
find
pronounc
infant
infect
rsv
compar
rv
consist
studi
demonstr
virusspecif
pattern
gene
express
interestingli
rsv
infect
b
cell
wherea
rv
bind
b
cell
induc
prolifer
combin
effect
viru
inflammatori
respons
lead
epitheli
damag
slough
mucu
product
ultim
airway
obstruct
lead
wheez
recent
find
crosssect
birth
cohort
studi
indic
environment
exposur
modifi
host
respons
respiratori
virus
earli
childhood
exampl
children
european
dairi
farm
less
like
transient
wheez
ill
mostli
viral
caus
similarli
children
wisconsin
dairi
farm
famili
fewer
medic
attend
respiratori
ill
compar
nonfarm
famili
lactobacillu
johnsonii
environment
microb
associ
pet
ownership
protect
rsvinduc
patholog
mous
model
urban
area
earlylif
exposur
high
level
indoor
allergen
cockroach
mous
cat
divers
microb
household
dust
relat
reduc
risk
recurr
wheez
final
evid
virus
bacteria
interact
patient
respiratori
ill
viral
infect
ill
associ
transient
detect
common
bacteri
pathogen
moraxella
catarrhali
streptococcu
pneumonia
haemophliu
influenza
furthermor
airway
microbiom
commun
domin
organ
associ
increas
risk
wheez
ill
final
hospit
rsvinduc
bronchiol
associ
airway
microbiom
domin
h
influenza
streptococcu
speci
turn
associ
enhanc
innat
immun
activ
sever
interact
factor
contribut
strong
linkag
virusinduc
wheez
ill
risk
childhood
asthma
fig
first
host
factor
predispos
children
sever
rvor
rsv
infect
later
asthma
second
viral
wheez
ill
might
damag
airway
promot
variabl
airway
obstruct
third
might
interact
risk
factor
environment
exposur
promot
asthma
final
antibiot
use
urban
increas
hygien
caus
loss
microbi
biodivers
measur
rich
speci
distribut
eventu
dysbiosi
imbal
microbi
ecosystem
promot
allerg
diseas
contrast
divers
microbi
commun
might
help
maintain
normal
airway
physiolog
viral
infect
therebi
moder
prevent
respiratori
symptom
suscept
rvinduc
bronchiolitisearli
wheez
seem
link
predisposit
preval
rvinduc
bronchiol
high
first
year
life
infant
recurr
moderatetosever
respiratori
ill
atop
famili
genet
variat
locu
increas
risk
rvinduc
wheez
earli
childhood
although
mechan
effect
still
unknown
notabl
farm
exposur
also
interact
polymorph
influenc
risk
allergi
asthma
addit
low
interferon
respons
secondari
young
age
allerg
sensit
could
increas
suscept
viral
infect
ill
mani
studi
link
rvinduc
wheez
earli
life
atop
biomark
allergenspecif
sensit
increas
eosinophil
count
nasal
mucu
blood
presenc
atop
eczema
addit
effect
asthma
risk
allergen
exposur
highaffin
ige
receptor
crosslink
shown
impair
virusinduc
type
iii
interferon
product
peripher
blood
cell
also
type
inflammatori
cytokin
inhibit
antivir
respons
airway
epitheli
cell
interact
rvinduc
wheez
atopi
like
becom
stronger
increas
age
children
preval
intens
respiratori
allergi
increas
age
interact
allerg
sensit
rvinduc
wheez
describ
exampl
rv
infect
allergen
enhanc
airway
epitheli
cell
product
promot
type
airway
inflamm
remodel
polymorph
link
intermedi
lateonset
wheez
allerg
sensit
first
line
defens
rv
infect
airway
epithelium
rel
resist
infect
undamag
disrupt
airway
epithelium
favor
rv
replic
open
way
deeper
cell
layer
rv
replic
activ
increas
number
intercellular
adhes
molecul
receptor
shown
ifng
vdr
tnx
sftpd
recent
vitro
studi
damag
barrier
function
airway
epithelium
also
lead
enhanc
absorpt
aeroallergen
invas
bacteri
pathogen
airway
wall
final
rv
contribut
airway
remodel
induc
vascular
endotheli
growth
factor
tgfb
chemoattract
airway
smooth
muscl
cell
effect
might
pronounc
rv
infect
earli
life
thu
repeat
rv
infect
extend
lower
airway
could
damag
airway
lead
remodel
airway
structur
rsvinduc
bronchiol
link
increas
risk
asthma
sever
acut
ill
relat
subsequ
risk
asthma
polymorph
number
gene
mostli
relat
immun
regul
associ
increas
risk
rsvinduc
bronchiol
asthma
tabl
ii
risk
factor
includ
young
age
low
lung
function
unlik
rvinduc
wheez
ill
atop
children
probabl
increas
risk
rsvinduc
bronchiol
risk
sever
rsv
infect
link
balanc
type
immun
respons
infant
sever
versu
mild
rsv
shown
reduc
ifng
express
pbmc
airway
cell
ifng
express
correl
subsequ
asthma
polymorph
lp
link
induct
type
immun
respons
factor
also
influenc
sever
rsvinduc
ill
children
recent
shown
mice
aeroallergeninduc
predispos
pneumovirusinduc
asthma
dampen
impair
ifna
ifnl
product
also
ifnb
immunemodul
properti
inhibit
eosinophil
asthmalik
pathophysiolog
pneumovirusinfect
mice
overal
rsvinduc
bronchiol
typic
affect
neonat
critic
time
window
lung
develop
therefor
might
longterm
influenc
murin
model
shown
rsv
infect
caus
lung
damag
prolif
stage
lung
growth
compar
equilibr
stage
neonat
regulatori
b
nbreg
cell
highli
permiss
rsv
infect
frequenc
nbreg
cell
predict
sever
acut
bronchiol
diseas
thu
nbreg
cell
activ
might
import
role
modul
earlylif
host
respons
rsv
rsv
infect
increas
express
nerv
growth
factor
ngf
receptor
develop
lung
ngf
control
structur
develop
nervou
system
abil
respond
environment
chang
neurotrophin
level
correl
intens
allerg
condit
includ
asthma
overexpress
ngf
could
lead
airway
hyperreact
rsv
infect
virus
nearli
acut
wheez
episod
associ
viral
infect
although
rv
rsv
commonli
caus
wheez
ill
contribut
virus
includ
enteroviru
bocaviru
parainfluenzaviru
coronavirus
metapneumoviru
influenza
viru
adenovirus
polyomavirus
also
detect
lower
airway
almost
alway
viral
pathogen
uncertain
whether
contribut
wheez
ill
note
rsvor
rvinduc
wheez
ill
associ
increas
risk
recurr
wheez
asthma
infect
lesser
sever
virus
ubiquit
remain
determin
whether
less
sever
infect
virus
virus
even
certain
bacteriophag
could
protect
acquisit
asthma
prevent
asthma
relat
viral
wheez
antivir
antiinflammatori
treatment
test
longterm
efficaci
prevent
recurr
wheez
asthma
palivizumab
mab
reduc
rate
sever
rsv
infect
decreas
recurr
wheez
followup
preterm
infant
affect
rate
atop
asthma
infant
initi
rvinduc
wheez
episod
cours
oral
prednisolon
decreas
time
initi
asthma
control
therapi
subgroup
children
high
rv
genom
load
interestingli
children
high
rv
genom
load
treat
placebo
requir
asthma
control
medic
within
month
studi
indic
prevent
strategi
target
either
viru
inflammatori
respons
could
help
prevent
recurr
wheez
perhap
asthma
phenotyp
sever
factor
contribut
asthma
exacerb
includ
infect
underus
asthma
control
medic
exposur
allergen
pollut
case
contribut
factor
especi
true
sever
exacerb
viral
infect
special
import
contribut
exacerb
especi
fall
spring
temper
climat
viral
respiratori
tract
infect
common
furthermor
viral
infect
play
major
role
season
peak
exacerb
coincid
return
children
school
summer
spring
break
among
plethora
respiratori
virus
caus
wheez
ill
rv
close
associ
exacerb
childhood
asthma
rv
caus
spectrum
ill
rang
asymptomat
infect
sever
lower
respiratori
tract
ill
also
true
children
asthma
fact
rv
infect
children
asthma
caus
exacerb
number
cofactor
associ
greater
likelihood
sever
rvinduc
ill
list
contribut
factor
quit
similar
infant
fig
children
asthma
sever
rvinduc
ill
accompani
increas
inflammatori
respons
promot
asthma
exacerb
viral
factor
rva
rvc
associ
wheez
ill
earli
childhood
virus
also
often
associ
exacerb
asthma
compar
rvb
rvc
might
strongli
associ
sever
exacerb
includ
requir
hospit
could
due
faster
replic
rate
induct
robust
cellular
respons
demonstr
cultur
differenti
airway
epitheli
cell
cohort
studi
rvb
j
allergi
clin
immunol
volum
number
infect
increas
risk
exacerb
might
slightli
increas
risk
exacerb
children
whose
asthma
greater
sever
host
factor
children
establish
asthma
allergi
genet
factor
increas
risk
virusinduc
wheez
ill
asthma
exacerb
allergi
import
factor
fact
allergi
viral
respiratori
tract
infect
synergist
increas
risk
acut
asthma
exacerb
effect
allergi
dose
relat
exampl
cohort
costa
rican
children
quantiti
dust
mite
ige
posit
associ
risk
rvinduc
asthma
exacerb
addit
boston
cohort
children
acut
exacerb
asthma
sever
acut
rvinduc
exacerb
posit
relat
ige
specif
either
dust
mite
mous
protein
furthermor
studi
children
asthma
monitor
viral
infect
peak
month
april
septemb
rv
infect
allerg
sensit
associ
greater
sever
rvinduc
respiratori
ill
rvinduc
symptom
asthma
recent
studi
omalizumab
prevent
ige
bind
receptor
establish
neutral
allerg
inflamm
enhanc
interferon
respons
reduc
rvinduc
ill
asthma
exacerb
exampl
urban
children
moderatetosever
asthma
random
treatment
either
standard
asthma
control
therapi
standard
therapi
plu
omalizumab
separ
studi
yearround
preseason
treatment
omalizumab
elimin
season
peak
exacerb
associ
viral
infect
analysi
weekli
sampl
nasal
secret
confirm
omalizumab
reduc
virusinduc
exacerb
effect
pronounc
children
sever
asthma
furthermor
omalizumab
increas
ifna
respons
blood
cell
stimul
rv
ex
vivo
find
suggest
omalizumab
neutral
ige
indirectli
improv
antivir
respons
theori
support
find
omalizumab
reduc
frequenc
quantiti
durat
rv
detect
nasal
secret
sampl
weekli
also
reduc
frequenc
rvinduc
cold
one
third
studi
children
acut
asthma
exacerb
rvinduc
exacerb
less
sever
children
treat
omalizumab
compar
control
collect
find
suggest
allerg
inflamm
impair
antivir
respons
fact
consider
evid
childhood
asthma
associ
reduc
interferon
respons
blood
cell
airway
epithelium
see
review
issu
edward
et
al
adult
allerg
asthma
inhal
ifnb
administ
cold
attempt
prevent
viral
exacerb
although
primari
end
point
achiev
ifnb
improv
lung
function
studi
popul
also
improv
asthma
control
subset
adult
sever
asthma
sever
genet
factor
link
risk
asthma
exacerb
factor
polymorph
associ
acut
sever
exacerb
young
children
includ
asthmarel
hospit
polymorph
code
region
lead
increas
express
cell
surfac
interestingli
cellsurfac
receptor
rvc
polymorph
lead
increas
rvc
cell
bind
replic
find
suggest
linkag
exacerb
asthma
due
greater
sever
rvc
infect
sever
environment
factor
influenc
sever
ill
rv
infect
increas
probabl
rvinduc
exacerb
children
asthma
observ
studi
demonstr
exposur
pollut
increas
sever
virusinduc
lower
respiratori
tract
symptom
reduct
lung
function
children
asthma
addit
high
exposur
allergen
children
allerg
asthma
increas
risk
virusinduc
exacerb
matern
stress
depress
associ
acut
wheez
ill
predominantli
viral
young
children
mechan
associ
unknown
due
enhanc
h
respons
impair
antivir
respons
measur
pbmc
vitamin
level
invers
relat
measur
asthma
sever
includ
hospit
sever
exacerb
howev
random
clinic
trial
vitamin
supplement
adult
low
vitamin
level
reduc
rate
clinic
cold
exacerb
rate
viral
infect
gener
recogn
import
contributor
acut
asthma
exacerb
howev
prospect
monitor
nasal
secret
peak
season
rv
infect
asthma
exacerb
provid
evid
close
relationship
viral
bacteri
respiratori
symptom
rv
infect
increas
frequenc
quantiti
pneumonia
catarrhali
h
influenza
detect
airway
secret
addit
viral
infect
associ
detect
common
bacteri
pathogen
like
symptomat
children
asthma
like
associ
asthma
exacerb
addit
studi
conduct
identifi
differ
microbiom
composit
asymptomat
viral
infect
compar
associ
asthma
exacerb
compar
baselin
sampl
rv
infect
sampl
acut
rvinduc
exacerb
increas
detect
moraxella
speci
contrast
asymptomat
infect
associ
increas
corynebacterium
speci
compar
baselin
sampl
find
suggest
rv
infect
modifi
upper
airway
microbiom
quantit
qualit
chang
airway
microbiom
modifi
probabl
rv
infect
lead
exacerb
asthma
respiratori
virus
interact
host
environment
factor
increas
risk
wheez
ill
infant
increas
risk
exacerb
asthmat
children
find
suggest
number
therapeut
opportun
reduc
frequenc
sever
viral
respiratori
ill
hope
secondari
effect
incid
exacerb
asthma
fig
search
goe
effect
antivir
vaccin
rv
rsv
sever
candid
current
clinic
trial
review
edward
et
al
antivir
approach
also
includ
strategi
enhanc
resist
multipl
respiratori
virus
administr
interferon
immunostimulatori
molecul
furthermor
search
identifi
biolog
exposur
eg
microb
protein
might
help
promot
develop
healthi
mucos
immun
respons
resist
viral
infect
research
airway
microbiom
identifi
number
intrigu
associ
bacteria
might
either
protect
viral
ill
add
problem
find
suggest
possibl
new
therapeut
approach
identifi
new
class
probiot
select
promot
resist
viral
ill
develop
strategi
inhibit
pathogen
bacteria
synerg
virus
add
ill
sever
latter
approach
could
involv
antibacteri
vaccin
probiot
target
antimicrobi
therapi
could
also
consid
although
potenti
benefit
must
weigh
select
antimicrobialresist
organ
possibl
shortand
longterm
detriment
effect
commens
benefici
airway
gut
bacteria
final
treatment
either
prevent
allergi
moder
sever
could
secondarili
boost
antivir
respons
also
reduc
inflammatori
respons
lead
airway
obstruct
remodel
collect
new
approach
provid
hope
new
insight
person
risk
factor
genet
allergi
antivir
immun
environment
exposur
farm
urban
microb
viral
virul
har
reduc
morbid
viral
respiratori
ill
childhood
asthma
know
risk
factor
rvinduc
wheez
earli
childhood
includ
low
lung
function
genet
predisposit
atop
characterist
combin
rvinduc
wheez
atopi
predict
high
likelihood
subsequ
childhood
asthma
risk
factor
rsvinduc
bronchiol
includ
genet
low
lung
function
young
age
atopi
rsvinduc
bronchiol
also
predict
recurr
wheez
childhood
asthma
airway
inflamm
predispos
earli
rvinduc
wheez
appear
respons
corticosteroid
medic
prevent
rsvinduc
bronchiol
antirsv
mab
palivizumab
decreas
risk
sever
rsvinduc
ill
recurr
wheez
perhap
nonatop
asthma
